Furthermore, based on the above findings, we developed a bicistronic CAR-T expressing anti-MUC1 CAR and NKG2D CAR to simultaneously eliminate myeloid-derived suppressor cells (MDSCs) and cancer cells, thereby enhancing tumor regression. The gene discussed is MUC1; the disease is neoplasm.